Table 2.
Baseline biomarker differences between patients with heart failure with preserved ejection fraction without and with diabetes
| Biomarker | n | Non‐DM (n = 132) | DM (n = 116) | P for trend |
|---|---|---|---|---|
| eGFR (mL/min/1.73 m2) | 248 | 67 (57, 77) | 57 (46, 73) | 0.003 |
| UPCR (mg/mmol) | 240 | 0.10 (0.07, 0.15) | 0.13 (0.08, 0.29) | 0.001 |
| Urinary protein level (mg/dL) | 240 | 7.0 (4.2, 13.0) | 9.8 (4.8, 23.6) | 0.005 |
| hs‐CRP (mg/L) | 232 | 2.4 (1.1, 5.6) | 3.1 (1.6, 7.5) | 0.046 |
| Uric acid (mg/dL) | 236 | 6.9 (5.6, 8.4) | 7.5 (6.4, 9.2) | 0.009 |
| NT‐proBNP (pg/mL) | 237 | 624 (338, 1235) | 629 (278, 1429) | 0.80 |
| hs‐TnT (ng/mL) | 237 | 5.7 (3.1, 12.4) | 7.1 (3.7, 14.2) | 0.17 |
| sST2 (ng/mL) | 235 | 28 (22, 32) | 28 (21, 35) | 0.36 |
| Aldosterone (ng/L) | 242 | 149 (120, 202) | 142 (113, 174) | 0.09 |
| PICP (ng/mL) | 218 | 140 (107, 169) | 127 (102, 155) | 0.29 |
| CITP (ng/mL) | 152 | 2.1 (1.1, 3.6) | 1.6 (0.9, 3.0) | 0.93 |
| PIIINP (ng/mL) | 218 | 22 (16, 30) | 28 (21, 36) | <0.001 |
| MMP‐2 (ng/mL) | 245 | 390 (313, 449) | 411 (353, 463) | 0.09 |
| MMP‐9 (ng/mL) | 245 | 312 (212, 479) | 335 (258, 474) | 0.12 |
| TIMP‐1 (ng/mL) | 245 | 188 (170, 212) | 212 (183, 245) | <0.001 |
| Gal‐3 (ng/mL) | 236 | 20 (16, 23) | 22 (18, 28) | <0.001 |
CITP, collagen type I; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; Gal‐3, galectin‐3; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐TnT, high‐sensitivity troponin T; MMP‐2, matrix metalloproteinase 2; MMP‐9, matrix metalloproteinase 9; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PICP, pro‐collagen type I carboxy‐terminal peptide; PIIINP, pro‐collagen type III amino‐terminal peptide; sST2, soluble ST2; TIMP1, tissue inhibitor of metalloproteinase 1; UPCR, urinary protein to creatinine ratio.